FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985620599> ?p ?o ?g. }

• W1985620599 endingPage "413" @default.
• W1985620599 startingPage "407" @default.
• W1985620599 abstract "Objective The purpose of this study was to compare the characteristics of patients with cervical cancer who were enrolled in cooperative group trials with characteristics of the cervical cancer population of the United States and to determine the generalizability of the results of those trials to the disease population in the United States. Study design Phase III trials in cervical cancer that were conducted by cooperative groups in the United States from 1981 through 1997 were identified. These groups were placed into 4 categories on the basis of disease stage and primary treatment modality: Stage IB, negative pelvic nodes that were treated with radical hysterectomy (n = 277 patients); Stage IB-IIA, positive pelvic nodes that were treated with radical hysterectomy (n = 239 patients); Stage IB2, negative pelvic and para-aortic nodes that were treated with radiation therapy (n = 369 patients); and Stage IIB-IVA, negative para-aortic nodes that were treated with radiation therapy (n = 1190 patients). For each category, comparable patients from the Surveillance, Epidemiology, and End Results (SEER) database were identified. The age and ethnic distributions of each study population and the distributions of the SEER program were compared. Results The age distributions were equivalent, except for patients with IB2 disease that was treated with radiation therapy where cooperative group subjects were more likely to be younger than 50 years, (odds ratio, 0.17; 95% CI, 0.11-0.26). A statistically significant higher proportion of black and Hispanic women enrolled in cooperative group studies in comparison with surveillance, epidemiology, and end results. Conclusion Hispanic and black women were recruited proportionately to cooperative group randomized cervical cancer trials in comparison to the United States population. The age distribution of the clinical trial population is also comparable to that of the general population. The purpose of this study was to compare the characteristics of patients with cervical cancer who were enrolled in cooperative group trials with characteristics of the cervical cancer population of the United States and to determine the generalizability of the results of those trials to the disease population in the United States. Phase III trials in cervical cancer that were conducted by cooperative groups in the United States from 1981 through 1997 were identified. These groups were placed into 4 categories on the basis of disease stage and primary treatment modality: Stage IB, negative pelvic nodes that were treated with radical hysterectomy (n = 277 patients); Stage IB-IIA, positive pelvic nodes that were treated with radical hysterectomy (n = 239 patients); Stage IB2, negative pelvic and para-aortic nodes that were treated with radiation therapy (n = 369 patients); and Stage IIB-IVA, negative para-aortic nodes that were treated with radiation therapy (n = 1190 patients). For each category, comparable patients from the Surveillance, Epidemiology, and End Results (SEER) database were identified. The age and ethnic distributions of each study population and the distributions of the SEER program were compared. The age distributions were equivalent, except for patients with IB2 disease that was treated with radiation therapy where cooperative group subjects were more likely to be younger than 50 years, (odds ratio, 0.17; 95% CI, 0.11-0.26). A statistically significant higher proportion of black and Hispanic women enrolled in cooperative group studies in comparison with surveillance, epidemiology, and end results. Hispanic and black women were recruited proportionately to cooperative group randomized cervical cancer trials in comparison to the United States population. The age distribution of the clinical trial population is also comparable to that of the general population." @default.
• W1985620599 created "2016-06-24" @default.
• W1985620599 creator A5007617851 @default.
• W1985620599 creator A5015432678 @default.
• W1985620599 creator A5048722393 @default.
• W1985620599 date "2005-02-01" @default.
• W1985620599 modified "2023-09-25" @default.
• W1985620599 title "Population characteristics in cervical cancer trials: Search for external validity" @default.
• W1985620599 cites W1498668468 @default.
• W1985620599 cites W1533171997 @default.
• W1985620599 cites W1898209140 @default.
• W1985620599 cites W1921920391 @default.
• W1985620599 cites W1926137745 @default.
• W1985620599 cites W1935824237 @default.
• W1985620599 cites W1967326783 @default.
• W1985620599 cites W1977125071 @default.
• W1985620599 cites W1977876039 @default.
• W1985620599 cites W1984279206 @default.
• W1985620599 cites W1987716198 @default.
• W1985620599 cites W1999738237 @default.
• W1985620599 cites W2004424837 @default.
• W1985620599 cites W2013847854 @default.
• W1985620599 cites W2041891945 @default.
• W1985620599 cites W2042211250 @default.
• W1985620599 cites W2044509971 @default.
• W1985620599 cites W2053429791 @default.
• W1985620599 cites W2070789376 @default.
• W1985620599 cites W2086798071 @default.
• W1985620599 cites W2091747195 @default.
• W1985620599 cites W2092449206 @default.
• W1985620599 cites W2122306923 @default.
• W1985620599 cites W2137686126 @default.
• W1985620599 cites W2157719711 @default.
• W1985620599 cites W2159922504 @default.
• W1985620599 cites W2170766960 @default.
• W1985620599 cites W2314753133 @default.
• W1985620599 cites W2324392028 @default.
• W1985620599 cites W2328935341 @default.
• W1985620599 cites W2411041906 @default.
• W1985620599 cites W2417014296 @default.
• W1985620599 doi "https://doi.org/10.1016/j.ajog.2004.08.027" @default.
• W1985620599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15695979" @default.
• W1985620599 hasPublicationYear "2005" @default.
• W1985620599 type Work @default.
• W1985620599 sameAs 1985620599 @default.
• W1985620599 citedByCount "10" @default.
• W1985620599 countsByYear W19856205992015 @default.
• W1985620599 countsByYear W19856205992016 @default.
• W1985620599 countsByYear W19856205992021 @default.
• W1985620599 countsByYear W19856205992023 @default.
• W1985620599 crossrefType "journal-article" @default.
• W1985620599 hasAuthorship W1985620599A5007617851 @default.
• W1985620599 hasAuthorship W1985620599A5015432678 @default.
• W1985620599 hasAuthorship W1985620599A5048722393 @default.
• W1985620599 hasConcept C105795698 @default.
• W1985620599 hasConcept C107130276 @default.
• W1985620599 hasConcept C121608353 @default.
• W1985620599 hasConcept C126322002 @default.
• W1985620599 hasConcept C141071460 @default.
• W1985620599 hasConcept C143998085 @default.
• W1985620599 hasConcept C146357865 @default.
• W1985620599 hasConcept C151730666 @default.
• W1985620599 hasConcept C156957248 @default.
• W1985620599 hasConcept C27158222 @default.
• W1985620599 hasConcept C2778220009 @default.
• W1985620599 hasConcept C2778527826 @default.
• W1985620599 hasConcept C2779391198 @default.
• W1985620599 hasConcept C2779494336 @default.
• W1985620599 hasConcept C2908647359 @default.
• W1985620599 hasConcept C29456083 @default.
• W1985620599 hasConcept C33923547 @default.
• W1985620599 hasConcept C509974204 @default.
• W1985620599 hasConcept C535046627 @default.
• W1985620599 hasConcept C71924100 @default.
• W1985620599 hasConcept C86803240 @default.
• W1985620599 hasConcept C99454951 @default.
• W1985620599 hasConceptScore W1985620599C105795698 @default.
• W1985620599 hasConceptScore W1985620599C107130276 @default.
• W1985620599 hasConceptScore W1985620599C121608353 @default.
• W1985620599 hasConceptScore W1985620599C126322002 @default.
• W1985620599 hasConceptScore W1985620599C141071460 @default.
• W1985620599 hasConceptScore W1985620599C143998085 @default.
• W1985620599 hasConceptScore W1985620599C146357865 @default.
• W1985620599 hasConceptScore W1985620599C151730666 @default.
• W1985620599 hasConceptScore W1985620599C156957248 @default.
• W1985620599 hasConceptScore W1985620599C27158222 @default.
• W1985620599 hasConceptScore W1985620599C2778220009 @default.
• W1985620599 hasConceptScore W1985620599C2778527826 @default.
• W1985620599 hasConceptScore W1985620599C2779391198 @default.
• W1985620599 hasConceptScore W1985620599C2779494336 @default.
• W1985620599 hasConceptScore W1985620599C2908647359 @default.
• W1985620599 hasConceptScore W1985620599C29456083 @default.
• W1985620599 hasConceptScore W1985620599C33923547 @default.
• W1985620599 hasConceptScore W1985620599C509974204 @default.
• W1985620599 hasConceptScore W1985620599C535046627 @default.
• W1985620599 hasConceptScore W1985620599C71924100 @default.
• W1985620599 hasConceptScore W1985620599C86803240 @default.
• W1985620599 hasConceptScore W1985620599C99454951 @default.

• next